Related Experiment Video
Updated: Jan 30, 2026
Establishment of Gastric Cancer Patient-derived Xenograft Models and Primary Cell Lines
Published on: July 19, 2019
Evaluation of TAK-264, an Antibody-Drug Conjugate in Pancreatic Cancer Cell Lines and Patient-Derived Xenograft
Anna R Schreiber1, Anna Nguyen1, Stacey M Bagby1
1Department of Medicine, Division of Medical Oncology, University of Colorado Anschutz Medical Campus, CO, USA.
Background:
Antibody-drug conjugates (ADCs) are an emerging technology consisting of an antibody, linker, and toxic agent, which have the potential to offer a targeted therapeutic approach. A novel target recently explored for the treatment of pancreatic cancer is guanylyl cyclase C (GCC). The objective of this study was to determine the anti-tumorigenic activity of TAK-264, an investigational ADC consisting of an antibody targeting GCC linked to a monomethyl auristatin E payload via a peptide linker.
Methods:
The antiproliferative effects of TAK-264 assessed in a panel of eleven pancreatic cancer cell lines. Additionally, ten unique pancreatic ductal adenocarcinoma cancer patient-derived xenograft models were treated with TAK-264 and the efficacy was determined. Baseline levels of GCC were analyzed on PDX models and cell lines. Immunoblotting was performed to evaluate the effects of TAK-264 on downstream effectors.
Results:
GCC protein expression was analyzed by immunoblotting in both normal and tumor tissue; marked increase in GCC expression was observed in tumor tissue. The in vitro experiments demonstrated a range of responses to TAK-264. Eight of the ten PDAC PDX models treated with TAK-264 demonstrated a statistically significant tumor growth inhibition. Immunoblotting demonstrated an increase in phosphorylated-HistoneH3 in both responsive and less responsive cell lines and PDAC PDX models treated with TAK-264. There was no correlation between baseline levels of GCC and response in either PDX or cell line models.
Conclusion:
TAK-264 has shown suppression activity in pancreatic cancer cell lines and in pancreatic PDX models. These findings support further investigation of ADC targeting GCC.
Insights
TAK-264, an antibody-drug conjugate targeting guanylyl cyclase C (GCC), demonstrated significant tumor growth inhibition in pancreatic cancer models. Further investigation into this targeted therapy is warranted.
Area of Science:
- Oncology
- Pharmacology
- Biotechnology
Background:
- Antibody-drug conjugates (ADCs) represent a targeted therapeutic strategy utilizing antibodies, linkers, and cytotoxic agents.
- Guanylyl cyclase C (GCC) is an emerging target for pancreatic cancer treatment.
- TAK-264 is an investigational ADC comprising an anti-GCC antibody and a monomethyl auristatin E payload.
Purpose of the Study:
- To evaluate the anti-tumorigenic activity of TAK-264 against pancreatic cancer.
- To assess the efficacy of TAK-264 in preclinical pancreatic cancer models.
Main Methods:
- Assessed antiproliferative effects of TAK-264 on eleven pancreatic cancer cell lines.
- Evaluated TAK-264 efficacy in ten pancreatic ductal adenocarcinoma patient-derived xenograft (PDX) models.
- Analyzed GCC expression and downstream signaling effects via immunoblotting.
Main Results:
- GCC expression was significantly elevated in tumor tissues compared to normal tissues.
- TAK-264 achieved statistically significant tumor growth inhibition in eight of ten PDAC PDX models.
- Increased phosphorylated-HistoneH3 indicated cellular proliferation inhibition, irrespective of baseline GCC levels.
Conclusions:
- TAK-264 exhibits potent suppression activity against pancreatic cancer cell lines and PDX models.
- These findings support the further clinical investigation of GCC-targeting ADCs like TAK-264.
More Related Videos
09:56Patient-derived Heterogeneous Xenograft Model of Pancreatic Cancer Using Zebrafish Larvae as Hosts for Comparative Drug Assessment
Published on: April 30, 2019
06:59Establishment of Zebrafish Patient-Derived Xenografts from Pancreatic Cancer for Chemosensitivity Testing
Published on: May 12, 2023
Related Concept Videos
02:50Conjugated Proteins
Nucleoproteins are protein complexes that contain nucleic acids, categorized as deoxyribonucleoproteins (DNPs) or ribonucleoproteins (RNPs) respectively. The nucleosome is a typical example of a DNP where nuclear DNA is associated with histone proteins. The major antigen for the Covid-19 virus SARS-CoV is an RNP that is critical...
01:16Cell Lines
01:15Drug Dosing: Geriatric Patients
01:21Drug Dosing: Obese Patients
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution